FDA Clears Gleamer’s ChestView AI Software for CXR
Adjunctive use of the AI-powered software led to an average 38.6 percent increase in the detection of pneumothorax by general radiologists, according to a 2023 study.
The Food and Drug Administration (FDA) has granted 510(k) clearance for ChestView, an artificial intelligence (AI)-enabled software, which may enhance detection of a variety of abnormalities on chest X-rays (CXRs).
In a 2023 retrospective study involving 500 patients, researchers found that adjunctive use of the ChestView software led to an average increased detection of 26.2 percent for pneumothorax, 8.5 percent for pleural effusion and 14.1 percent for consolidation.
Without AI assistance, only two out of 12 reviewing radiologists were able to detect a right paravertebral mass in the case above. With the use of the newly FDA cleared AI software ChestView, all 12 radiologists detected the mass. (Images courtesy of Radiology.)
The authors of the study, published in Radiology, also noted an overall mean 31 percent reduction in CXR reading time with the use of ChestView. Specifically, researchers pointed out a 27 percent reduction in CXR reading time for thoracic radiologists and a 30 percent reduction for radiology residents.
"We believe ChestView will transform how chest X-rays are analyzed, making healthcare delivery faster, safer, and more effective for millions of patients,” noted Christian Allouche, the chief executive officer at Gleamer.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.
